Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-26
DOI
10.1186/s12933-020-01209-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of the dual sodium‐glucose linked transporter inhibitor, licogliflozin versus placebo or empagliflozin in patients with type 2 diabetes and heart failure
- (2020) Rudolf A. Boer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
- (2020) Ayako Fuchigami et al. Cardiovascular Diabetology
- Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
- (2020) Kim A. Connelly et al. Cardiovascular Diabetology
- Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure
- (2020) Nikole J. Byrne et al. Circulation-Heart Failure
- Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis
- (2020) Sean McGrath et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
- (2020) Jianhong Zhu et al. Lancet Diabetes & Endocrinology
- Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Meta-Analysis of Randomized Clinical Trials
- (2020) Kris Kumar et al. AMERICAN JOURNAL OF MEDICINE
- Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
- (2020) In-Chang Hwang et al. Cardiovascular Diabetology
- Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects
- (2020) Matthew Griffin et al. CIRCULATION
- Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
- (2020) Jagdeep S.S. Singh et al. DIABETES CARE
- The Effects of Canagliflozin compared to Sitagliptin on Cardiorespiratory Fitness in Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction: Results of the CANA‐HF Study
- (2020) Salvatore Carbone et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Glucagon‐Like Peptide‐1 Receptor Agonists, Sodium‐Glucose Cotransporter‐2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12‐Month Treatment
- (2020) Ignatios Ikonomidis et al. Journal of the American Heart Association
- Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction
- (2020) Jonathan W. Cunningham et al. JACC-Heart Failure
- Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
- (2020) Atsushi Tanaka et al. ESC Heart Failure
- Meta-analysis Assessing the Effect of Sodium-glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus
- (2020) Dimitrios Patoulias et al. AMERICAN JOURNAL OF CARDIOLOGY
- A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
- (2020) Alexander J M Brown et al. EUROPEAN HEART JOURNAL
- Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial
- (2020) Mie K. Eickhoff et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
- (2020) Kentaro Ejiri et al. Journal of the American Heart Association
- Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
- (2020) Natalie A. Mordi et al. CIRCULATION
- Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients ― A Randomized Controlled Trial ―
- (2020) Hiroyuki Kayano et al. CIRCULATION JOURNAL
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
- (2020) Stefan D. Anker et al. CIRCULATION
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus
- (2020) Chi Young Shim et al. CIRCULATION
- Heart Failure With Preserved Ejection Fraction and Diabetes
- (2019) Kelly McHugh et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?
- (2019) Carlos G. Santos-Gallego et al. CARDIOVASCULAR DRUGS AND THERAPY
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
- (2019) Ting-I Lee et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure
- (2019) William T. Abraham et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
- (2019) Benedetta Maria Bonora et al. Cardiovascular Diabetology
- Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
- (2019) Subodh Verma et al. CIRCULATION
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
- (2019) Vinay Garg et al. PROGRESS IN CARDIOVASCULAR DISEASES
- The effects of sodium‐glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions
- (2019) Nick S.R. Lan et al. ESC Heart Failure
- Effect of sodium glucose cotransporter 2 inhibitors on cardiac function and cardiovascular outcome: a systematic review
- (2019) Koichiro Matsumura et al. Cardiovascular Ultrasound
- 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETES CARE
- European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
- (2019) Petar M. Seferović et al. EUROPEAN JOURNAL OF HEART FAILURE
- Dynamics of Epicardiac Fat and Heart Function in Type 2 Diabetic Patients Initiated with SGLT-2 Inhibitors
- (2019) Adina Braha et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes
- (2018) Daisuke Matsutani et al. Cardiovascular Diabetology
- Diabetic Cardiomyopathy
- (2018) Guanghong Jia et al. CIRCULATION RESEARCH
- Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus
- (2018) Hidekazu Tanaka et al. HEART FAILURE REVIEWS
- Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
- (2018) W. Timothy Garvey et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction
- (2017) G. Michael Felker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
- (2017) James L. Januzzi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Incremental prognostic value of global longitudinal strain in patients with type 2 diabetes mellitus
- (2016) Ju-Hua Liu et al. Cardiovascular Diabetology
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure
- (2016) Michael R. Zile et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis
- (2016) Heidi Storgaard et al. PLoS One
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Global Longitudinal Strain Is a Superior Predictor of All-Cause Mortality in Heart Failure With Reduced Ejection Fraction
- (2015) Morten Sengeløv et al. JACC-Cardiovascular Imaging
- Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
- (2015) Alessandra Dei Cas et al. JACC-Heart Failure
- Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
- (2015) Xiang Wan et al. BMC Medical Research Methodology
- Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure
- (2014) Gianluigi Savarese et al. JACC-Heart Failure
- Impaired Systolic Function by Strain Imaging in Heart Failure With Preserved Ejection Fraction
- (2013) Elisabeth Kraigher-Krainer et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
- (2008) M. R. MacDonald et al. EUROPEAN HEART JOURNAL
- Meta-analysis of skewed data: Combining results reported on log-transformed or raw scales
- (2008) Julian P. T. Higgins et al. STATISTICS IN MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now